PURPOSE: The goal of this research is to develop stable formulations for live attenuated influenza vaccines (LAIV) by employing the drying methods freeze drying, spray drying, and foam drying. METHODS: Formulated live attenuated Type-A H1N1 and B-strain influenza vaccines with a variety of excipient combinations were dried using one of the three drying methods. Process and storage stability at 4, 25 and 37°C of the LAIV in these formulations was monitored using a TCID50 potency assay. Their immunogenicity was also evaluated in a ferret model. RESULTS: The thermal stability of H1N1 vaccine was significantly enhanced through application of unique formulation combinations and drying processes. Foam dried formulations were as much as an order of magnitude more stable than either spray dried or freeze dried formulations, while exhibiting low process loss and full retention of immunogenicity. Based on long-term stability data, foam dried formulations exhibited a shelf life at 4, 25 and 37°C of >2, 1.5 years and 4.5 months, respectively. Foam dried LAIV Type-B manufactured using the same formulation and process parameters as H1N1 were imparted with a similar level of stability. CONCLUSION: Foam drying processing methods with appropriate selection of formulation components can produce an order of magnitude improvement in LAIV stability over other drying methods.
PURPOSE: The goal of this research is to develop stable formulations for live attenuated influenza vaccines (LAIV) by employing the drying methods freeze drying, spray drying, and foam drying. METHODS: Formulated live attenuated Type-A H1N1 and B-strain influenza vaccines with a variety of excipient combinations were dried using one of the three drying methods. Process and storage stability at 4, 25 and 37°C of the LAIV in these formulations was monitored using a TCID50 potency assay. Their immunogenicity was also evaluated in a ferret model. RESULTS: The thermal stability of H1N1 vaccine was significantly enhanced through application of unique formulation combinations and drying processes. Foam dried formulations were as much as an order of magnitude more stable than either spray dried or freeze dried formulations, while exhibiting low process loss and full retention of immunogenicity. Based on long-term stability data, foam dried formulations exhibited a shelf life at 4, 25 and 37°C of >2, 1.5 years and 4.5 months, respectively. Foam dried LAIV Type-B manufactured using the same formulation and process parameters as H1N1 were imparted with a similar level of stability. CONCLUSION: Foam drying processing methods with appropriate selection of formulation components can produce an order of magnitude improvement in LAIV stability over other drying methods.
Authors: Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Emilie Pan; Yi Ao; Devendra S Kalonia; Michael J Pikal Journal: Pharm Res Date: 2007-02-15 Impact factor: 4.200
Authors: Ozan S Kumru; Sangeeta B Joshi; Dawn E Smith; C Russell Middaugh; Ted Prusik; David B Volkin Journal: Biologicals Date: 2014-07-01 Impact factor: 1.856
Authors: Satoshi Ohtake; Russell A Martin; Luisa Yee; Dexiang Chen; Debra D Kristensen; David Lechuga-Ballesteros; Vu Truong-Le Journal: Vaccine Date: 2009-11-25 Impact factor: 3.641
Authors: Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Lauren Nguyen; Devendra S Kalonia; Marcus T Cicerone; Michael J Pikal Journal: J Pharm Sci Date: 2007-08 Impact factor: 3.534
Authors: Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury Journal: NPJ Vaccines Date: 2020-05-18 Impact factor: 7.344
Authors: Ahmad M Aldossary; Chinedu S M Ekweremadu; Ifunanya M Offe; Haya A Alfassam; Sooyeon Han; Vivian C Onyali; Chukwuebuka H Ozoude; Emmanuel A Ayeni; Chinekwu S Nwagwu; Abdulrahman A Halwani; Nada H Almozain; Essam A Tawfik Journal: Saudi Pharm J Date: 2022-03-15 Impact factor: 4.562
Authors: Vincent Leung; Jonathan Mapletoft; Ali Zhang; Amanda Lee; Fatemeh Vahedi; Marianne Chew; Alexandra Szewczyk; Sana Jahanshahi-Anbuhi; Jann Ang; Braeden Cowbrough; Matthew S Miller; Ali Ashkar; Carlos D M Filipe Journal: Sci Rep Date: 2019-05-21 Impact factor: 4.379
Authors: Jasmine Tomar; Harshad P Patil; Gustavo Bracho; Wouter F Tonnis; Henderik W Frijlink; Nikolai Petrovsky; Rita Vanbever; Anke Huckriede; Wouter L J Hinrichs Journal: J Control Release Date: 2018-09-12 Impact factor: 9.776
Authors: Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury Journal: NPJ Vaccines Date: 2020-05-18 Impact factor: 7.344
Authors: Jasmine Tomar; Wouter F Tonnis; Harshad P Patil; Anne H de Boer; Paul Hagedoorn; Rita Vanbever; Henderik W Frijlink; Wouter L J Hinrichs Journal: Acta Pharm Sin B Date: 2019-05-28 Impact factor: 11.413